{
    "ticker": "MDWD",
    "name": "MediWound Ltd.",
    "description": "MediWound Ltd. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for tissue repair and regeneration. Founded in 2001 and headquartered in Yavne, Israel, MediWound's primary focus is on advanced wound care and the treatment of severe burns. The company's lead product, NexoBrid, is an enzymatic debridement agent designed to remove dead tissue from burn wounds, enabling faster healing and improved outcomes. NexoBrid has received regulatory approval in multiple countries and is already being used in hospitals worldwide. MediWound is also committed to expanding its product pipeline, with ongoing research and development efforts aimed at addressing unmet medical needs in wound care and regenerative medicine. By leveraging its proprietary technology and scientific expertise, MediWound strives to improve patient care and enhance recovery for individuals with complex and chronic wounds. The company is actively pursuing opportunities for collaboration and partnerships to accelerate product development and broaden its market reach. With a strong emphasis on innovation and clinical efficacy, MediWound is positioned to become a leader in the biopharmaceutical industry, particularly in the field of advanced wound care.",
    "industry": [
        "Biopharmaceuticals",
        "Medical Devices"
    ],
    "headquarters": "Yavne, Israel",
    "founded": "2001",
    "website": "https://www.mediwound.com",
    "ceo": "Gal Cohen",
    "social_media": {
        "twitter": "https://twitter.com/MediWound",
        "linkedin": "https://www.linkedin.com/company/medi-wound/"
    },
    "investor_relations": "https://www.mediwound.com/investor-relations",
    "key_executives": [
        {
            "name": "Gal Cohen",
            "position": "CEO"
        },
        {
            "name": "Shai Meretzki",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Wound Care Products",
            "products": [
                "NexoBrid"
            ]
        },
        {
            "category": "Regenerative Medicine",
            "products": [
                "EscharEx"
            ]
        }
    ],
    "seo": {
        "meta_title": "MediWound Ltd. | Innovative Biopharmaceutical Solutions for Wound Care",
        "meta_description": "Explore MediWound Ltd., a biopharmaceutical company focused on advanced wound care solutions, including the innovative NexoBrid for burn treatment.",
        "keywords": [
            "MediWound",
            "NexoBrid",
            "Wound Care",
            "Biopharmaceuticals",
            "Burn Treatment",
            "Tissue Repair"
        ]
    },
    "faq": [
        {
            "question": "What is MediWound known for?",
            "answer": "MediWound is known for its innovative products in advanced wound care, particularly the enzymatic debridement agent NexoBrid."
        },
        {
            "question": "Who is the CEO of MediWound?",
            "answer": "Gal Cohen is the CEO of MediWound Ltd."
        },
        {
            "question": "Where is MediWound headquartered?",
            "answer": "MediWound is headquartered in Yavne, Israel."
        },
        {
            "question": "What are MediWound's main products?",
            "answer": "MediWound's main products include NexoBrid and EscharEx."
        },
        {
            "question": "When was MediWound founded?",
            "answer": "MediWound was founded in 2001."
        }
    ],
    "competitors": [
        "AVNS",
        "CRMD",
        "XLRN"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "MRK",
        "BMY"
    ]
}